Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
复制标题
DOI：
10.1016/j.clinthera.2011.05.044
复制
发表时间：
2011-06
影响因子：
3.2
通讯作者：
Singh JA
中科院分区：
文献类型：
--
作者：
Curtis JR;Singh JA
风湿性关节炎（RA）是一种常见的炎症性自身免疫性疾病，给医疗保健系统带来了巨大的负担。虽然目前还没有治愈RA的方法，但近年来对RA疾病发病机制的认识有所提高，导致了旨在靶向RA炎症反应的特定因素的新生物治疗的发展。为管理式护理环境中负责决策的个人（包括药剂师、医生和其他医疗保健专业人员）提供目前用于治疗RA的生物疗法的综述。研究治疗类风湿关节炎也进行了讨论。对关于生物疗法治疗RA的同行评审、已发表文献进行了叙述性综述。RA的治疗旨在实现尽可能低的疾病活动性和理想的缓解。靶向免疫反应特定组分的生物制剂在减轻中重度RA患者的RA症状、减缓疾病进展速度、改善身体功能和生活质量方面非常有效。给药时间表和给药途径取决于所使用的生物制剂，这些因素影响治疗成本以及患者和医生的偏好。在过去的十年中，随着几种靶向生物制剂的引入，RA的治疗已经发生了变化。虽然生物制剂在短期内比传统的疾病缓解抗风湿药物更昂贵，但药物特异性成本可能会被RA症状的显着改善，疾病进展减缓以及患者身体功能和生活质量的改善所抵消。
Rheumatoid arthritis (RA) is a common inflammatory autoimmune disease that places a substantial burden on health care systems. Although there is currently no cure for RA, improved understanding of RA disease pathogenesis in recent years has led to the development of new biologic treatments designed to target specific elements of the RA inflammatory response. To provide individuals responsible for decision making within managed care environments, including pharmacists, physicians, and other healthcare professionals, with a review of biologic therapies currently used for the treatment of RA. Investigational treatments for RA are also discussed. A narrative review of the peer-reviewed, published literature on biologic therapies in the treatment of RA was performed. The treatment of RA is aimed at achieving the lowest possible disease activity and ideally remission. Biologic agents that target specific components of the immune response are highly effective in reducing RA symptoms, slowing the rate of disease progression, and improving physical function and quality of life measures in patients with moderate to severe RA. Dosing schedules and routes of administration vary depending on the biologic used, and these factors influence the cost of therapy and patient and physician preference. The treatment of RA has been transformed in the last decade with the introduction of several targeted biologic agents. Although biologic agents are more costly in the short term than conventional disease-modifying antirheumatic drugs, drug-specific costs may be offset by significant improvements in RA symptoms, slowed disease progression, and improved physical function and quality of life for patients.
登录
查看更多内容
影响因子：
--
作者：
Cohen, Stanley B.;Emery, Paul;Totoritis, Mark C.
通讯作者：
Totoritis, Mark C.
影响因子：
--
作者：
Cohen, S;Hurd, E;McCabe, D
通讯作者：
McCabe, D
影响因子：
5.5
作者：
Ariza-Ariza, R.;Navarro-Sarabia, F.;Toyos, J.
通讯作者：
Toyos, J.
影响因子：
--
作者：
Breedveld, FC;Weisman, MH;Spencer-Green, GT
通讯作者：
Spencer-Green, GT
影响因子：
--
作者：
Clair, EWS;van der Heijde, DMFM;Baker, D
通讯作者：
Baker, D